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Introduction
Pooled 48-week primary analysis results of two double-
blind, randomised, TMC278 Phase III trials, ECHO
(TMC278-C209, NCT00540449) and THRIVE
(TMC278-C215, NCT00543725), are presented.
Methods
Treatment-naïve adult patients (N=1368) received (1:1)
TMC278 25mg qd or EFV 600mg qd, plus TDF/FTC
( E C H O ) ,o rT D F / F T C ,A Z T / 3 T Co rA B C / 3 T C
(THRIVE). The primary objective was to demonstrate
non-inferiority (12% margin) of TMC278 to EFV in con-
firmed virologic response (viral load [VL] <50 copies/mL
ITT-TLOVR algorithm) at Week 48.
Results
Overall virologic response rates at Week 48 were high
(Figure 1).TMC278 showed non-inferior efficacy versus
EFV. The impact of adherence, in addition to other fac-
tors, such as baseline viral load and exposure, on virolo-
g i cr e s p o n s ew i l lb ep r e s e n t e d .I n c i d e n c e so ft h e
following tolerability measures were significantly lower
i nt h eT M C 2 7 8g r o u pt h a ni nt h eE F Vg r o u p :a d v e r s e
events (AEs) leading to discontinuation (3% vs. 8%,
respectively; p=0.0005), grade 2-4 AEs at least possibly
related to treatment (16% vs. 31%; p<0.0001), rash (3%
vs 14%; p<0.0001), dizziness (8% vs. 26%; p<0.0001),
abnormal dreams/nightmare (8% vs. 13%; p=0.0061),
and grade 3/4 laboratory abnormalities for lipids
(p≤0.001).
Conclusions
At Week 48, TMC278 demonstrated a high virologic
response rate (≥83%) and non-inferior efficacy versus
EFV when administered with NRTIs in both Phase III
trials. The virologic failure rate was significantly higher
with TMC278, while the incidences of AEs leading to
discontinuation were significantly lower with TMC278.
Grade 2-4 AEs at least possibly related to treatment
were half as frequent with TMC278 compared with
EFV. In addition, incidences of dizziness, abnormal
dreams/nightmare and rash were significantly lower for
TMC278, and TMC278 had significantly fewer grade 3/
4 lipid abnormalities than EFV.
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